The WACC of Bionik Laboratories Corp (BNKL) is 3.7%.
| Range | Selected | |
| Cost of equity | 3.30% - 109.60% | 56.45% |
| Tax rate | 26.20% - 27.00% | 26.60% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 3.7% - 3.7% | 3.7% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | -22.52 | 0.31 |
| Additional risk adjustments | 103.0% | 103.5% |
| Cost of equity | 3.30% | 109.60% |
| Tax rate | 26.20% | 27.00% |
| Debt/Equity ratio | 1727.35 | 1727.35 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 3.7% | 3.7% |
| Selected WACC | 3.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BNKL:
cost_of_equity (56.45%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (-22.52) + risk_adjustments (103.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.